HomeCompareTSBX vs EPRT

TSBX vs EPRT: Dividend Comparison 2026

TSBX yields 563.38% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSBX wins by $156403.99M in total portfolio value
10 years
TSBX
TSBX
● Live price
563.38%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$156404.05M
Annual income
$115,926,179,183.70
Full TSBX calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — TSBX vs EPRT

📍 TSBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSBXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSBX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSBX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSBX
Annual income on $10K today (after 15% tax)
$47,887.32/yr
After 10yr DRIP, annual income (after tax)
$98,537,252,306.14/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, TSBX beats the other by $98,537,241,110.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSBX + EPRT for your $10,000?

TSBX: 50%EPRT: 50%
100% EPRT50/50100% TSBX
Portfolio after 10yr
$78202.06M
Annual income
$57,963,096,177.28/yr
Blended yield
74.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

TSBX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Price Target
$0.50
+40.8% upside vs current
Range: $0.50 — $0.50
Altman Z
-23.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSBX buys
0
EPRT buys
0
No recent congressional trades found for TSBX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSBXEPRT
Forward yield563.38%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$156404.05M$64.3K
Annual income after 10y$115,926,179,183.70$13,170.85
Total dividends collected$152979.84M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$0.50$35.50

Year-by-year: TSBX vs EPRT ($10,000, DRIP)

YearTSBX PortfolioTSBX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$67,038$56,338.03$11,212$512.01+$55.8KTSBX
2$424,702$352,971.06$12,689$692.09+$412.0KTSBX
3$2,544,295$2,089,864.53$14,521$944.30+$2.53MTSBX
4$14,423,258$11,700,861.61$16,841$1,302.88+$14.41MTSBX
5$77,424,065$61,991,178.81$19,841$1,821.64+$77.40MTSBX
6$393,842,555$310,998,805.50$23,818$2,587.47+$393.82MTSBX
7$1,899,912,512$1,478,500,978.24$29,230$3,744.65+$1899.88MTSBX
8$8,698,653,014$6,665,746,626.53$36,816$5,540.38+$8698.62MTSBX
9$37,829,785,494$28,522,226,769.44$47,806$8,413.17+$37829.74MTSBX
10$156,404,049,663$115,926,179,183.70$64,324$13,170.85+$156403.99MTSBX

TSBX vs EPRT: Complete Analysis 2026

TSBXStock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Full TSBX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this TSBX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSBX vs SCHDTSBX vs JEPITSBX vs OTSBX vs KOTSBX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.